Table 3 Results of binomial logistic regression analysis to stratify DCB and NDB patients.

From: CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer

Characteristics

OR (95%CI)

P value

CD57+CD8+ T cells/T cells ratio (%)

0.666 (0.448, 0.001)

0.045*

CD8+ T cells/T cells ratio (%)

1.021 (0.838, 1.245)

0.834

PD-L1 status

 Negative

Reference

 

 Positive

0.950 (0.050, 18.042)

0.974

  1. *p < 0.05, DCB durable clinical benefit, NDB no durable clinical benefit, PD-L1 Programmed death-ligand 1.
  2. The bold value of 0.045 is highlighted to emphasize the significant difference in the CD57+CD8+ T cells/Tcells ratio when distinguishing between patients with DCB and NDB.
Back to article page